Johnson & Johnson competitors

Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 47,000 people worldwide and markets medicines in more than 175 countries. Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada.

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Michael F. Mahoney is a Director on the board of the Boys & Girls Club of Boston. He is the Chairman and CEO of Boston Scientific.

Dr. Caforio has been our Chief Executive Officer since May 2015. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization. Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and a member of the Business Roundtable, CEO Roundtable on Cancer and the Pharmaceutical Research and Manufacturers of America (PhRMA) and The Prium.

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM. I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors. I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Philip 'Phil' Blake is an Head:US Region at Bayer Schering Pharma, President/CEO at Bayer, and Board Member at Nexia Biotechnologies. He has worked as Exec VP at Bayer, Senior VP at Bayer, and Head at Bayer HealthCare.

Joined RB as CEO-Designate in July 2019 and was appointed as CEO on 1 September 2019. Prior to joining RB, Laxman held various roles at PepsiCo from 2012 to 2019. He was previously Chief Executive Officer of PepsiCo’s Latin America, Europe and Sub-Saharan Africa operations, where he ran the Company's food and beverage businesses across the regions. Prior to PepsiCo, Laxman served as a Director for McKinsey & Company and held various roles from 1993 to 2012. He was also an Advisory Board member of the Jay H. Baker Retailing Centre at the Wharton School, University of Pennsylvania. Laxman holds a degree in Mechanical Engineering from the College of Engineering, University of Pune, India. He has an MA in German and International Studies from The Lauder Institute at the University of Pennsylvania and an MBA in Finance from The Wharton School at The University of Pennsylvania.